title: Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis.
authors.affiliation: Department of Dermatology.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Honda
authors.affiliation: Department of Dermatology.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Otsuka
authors.affiliation: Department of Dermatology.
authors.forename: Gyohei
authors.initials: G
authors.lastname: Egawa
authors.affiliation: Department of Neurology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawara, Sakyo, Kyoto 606-8507, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Inoue
authors.affiliation: Department of Neurology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawara, Sakyo, Kyoto 606-8507, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kuzuya
authors.affiliation: Department of Neurology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawara, Sakyo, Kyoto 606-8507, Japan.
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Takahashi
authors.affiliation: Department of Dermatology.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Miyachi
authors.affiliation: Department of Dermatology.
authors.forename: Kenji
authors.initials: K
authors.lastname: Kabashima
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D001933:Brain Stem / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging / Q000379:methods; D008582:Meningitis, Aseptic / Q000139:chemically induced* / Q000473:pathology; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000473:pathology; D018570:Risk Assessment; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab